台寶生醫股份有限公司
  • About Us
    • Company Overview
    • Team
    • Consultant
    • Location
  • Science
    • FAST CGT Platform
    • Pipeline
    • TDM
  • Investors
    • Corporate Governance
      • Board of Directors
        • Board Composition
        • Board Resolutions
        • Board Execution Status
      • Committees
        • Audit Committee
        • Compensation Committee
      • Corporate Governance Officer
      • Major Internal Policies
    • Financials
      • Monthly Revenue
      • Financial Reports
    • Shareholder Services
      • Major Shareholders
      • Meeting Information
      • Stakeholder Contact
      • Prospectuses
      • Material Information
      • Dividend and Stock
    • Investor Conference
        Investor Conference
    • Interested Parties
        Interested Parties
  • ESG
  • Press Center
    • Press Release
    • Public Announcement
  • Contact
  • Language｜ 繁中 EN
Press Center
  1. Home
  2. Press Center
  3. Public Announcement
Press Release Public Announcement
062025.02
Public Announcement
本公司美國子公司PhiBio Therapeutics Inc.自體細胞新藥 TRK-001取得台灣衛生福利部原則同意進行預防活體腎臟移植受 贈者排斥反應之二期人體臨床試驗
042025.02
Public Announcement
更正本公司初次申請上市、櫃(興櫃)或TDR用之公開說明書 部分內容
  • 1
台寶生醫股份有限公司
台寶生醫股份有限公司
Taiwan Bio Therapeutics INC.
Taipei ​| Office
5F., No. 501, Sec. 2, Tiding Blvd., Neihu Dist., Taipei City , Taiwan (R.O.C.) +886-2-2695-6382 info@twbio-thera.com
Hsin Chu | Manufacturing Site
4F., No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County , Taiwan (R.O.C.) +886-3-6684788#2020 info@twbio-thera.com
About Us Science Investors ESG Press Center Contact
Copyright © 2025 台寶生醫股份有限公司. All Rights Reserved.Design By Choice